新型及未来肠外脂质紊乱治疗药物
New and Future Parenteral Therapies for the Management of Lipid Disorders.
机构信息
Unidad Médica de Alta Especialidad, Hospital de Cardiologia No. 34 Instituto Mexicano del Seguro Social, Monterrey, NL, México.
Piedmont Heart Institute in Atlanta, Atlanta, GA, USA.
出版信息
Arch Med Res. 2018 Nov;49(8):538-547. doi: 10.1016/j.arcmed.2019.01.001. Epub 2019 Feb 8.
Cardiovascular disease (CVD) is the leading cause of death in the world. According to the World Health Organization, an estimated 17.9 million people died from CVD in 2016, representing 31% of all global deaths. Of these deaths, 5% are due to myocardial infarction and stroke. Dyslipidemia is known as the major risk factor of atherosclerotic cardiovascular disease. With current therapies, about 60% of high-risk CVD patients do not achieve LDL-C goals, and in patients with familiar hypercholesterolemia (FH) at maximum intensity statin treatment, only 20% achieve LDL-C goals. We discuss new and future parenteral therapies for the management of lipid disorders.
心血管疾病（CVD）是世界上的主要死因。根据世界卫生组织的数据，2016 年全球约有 1790 万人死于 CVD，占全球总死亡人数的 31%。其中，5%是由于心肌梗死和中风导致的。血脂异常是动脉粥样硬化性心血管疾病的主要危险因素。目前的治疗方法中，约 60%的高危 CVD 患者无法达到 LDL-C 目标，而在最大强度他汀类药物治疗下患有家族性高胆固醇血症（FH）的患者中，只有 20%能够达到 LDL-C 目标。我们讨论了管理血脂紊乱的新的和未来的肠外治疗方法。
Zotero 插件